RE: Off topic but..21 Aug 2025 12:27
This repeated argument is nonsense anyway Thorn because it was a P1a trial across a load of different indications for exactly that reason, to uncover the best indication/s to take forward into an expansion trial. That happens to be SGC, TNBC & STS, so your claims are wildly exaggerated (that STS is a dud and SGC was a lucky fluke) and instead all that’s happened is, given limited finances, SGC now appears to be the lowest risk/highest chance of success + quickest route to approval.
Yes STS was originally top of the list but during data collection moved to third in the pecking order, isn’t that pretty standard?